Business

OxyContin maker to offer abuse-resistant Zohydro

WASHINGTON — The maker of OxyContin said it has completed testing of an abuse-resistant version of the painkiller hydrocodone, a surprise development that could derail sales of the recently launched Zohydro, a similar medication that has been criticized for lacking such safeguards.

Purdue Pharma said it plans to submit its extended-release hydrocodone drug to the Food and Drug Administration later this year. The tablets are designed to prevent users from crushing them for snorting or injection.

Advertisement

Shares of rival Zogenix Inc. plunged more than 20 percent after the announcement, which appears to jeopardize sales of the company’s Zohydro. Physicians would presumably be more likely to prescribe a harder-to-abuse form of hydrocodone to try to protect their patients from addiction and abuse. And the Food and Drug Administration could potentially pull Zogenix’s drug off the market if its regulators determine that a safer alternative is available.

Zogenix began shipping Zohydro to pharmacies last week.

Get Business Headlines in your inbox:
The Globe's latest business headlines delivered every morning, Monday through Friday.
Thank you for signing up! Sign up for more newsletters here

Purdue Pharma said a study of its once-a-day hydrocodone pill showed positive results in a 588-patient study of low back pain. Sixty-five percent of patients experienced at least a 30 percent reduction in their pain, while 48 percent reported a 50 percent reduction in pain, according to the company. Purdue Pharma’s formulation would last longer than Zohydro, which is designed to be taken twice a day. Pain experts said both durations are important for treating different types of conditions and patients.

‘‘As a pain specialist, and specifically a cancer pain specialist, I think we are always interested in adding more tools to our toolbox,’’ said Larry Driver, a professor at the MD Anderson Cancer Center in Houston. It boils down to individualizing patient care to prescribe the safest and most effective regimen available.’’

However, patient safety advocates said Wednesday there are already too many prescription narcotics available.

Associated Press

Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.